Literature DB >> 7562945

Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles.

L B Townsend1, R V Devivar, S R Turk, M R Nassiri, J C Drach.   

Abstract

A new series of 2-substituted 5,6-dichlorobenzimidazole ribonucleosides has been synthesized and tested for activity against two human herpes viruses and for cytotoxicity. 2,5,6-Trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB) was prepared by ribosylation of the heterocycle 2,5,6-trichlorobenzimidazole followed by a removal of the protecting groups. The 2-bromo derivative (BDCRB) was made in a similar fashion from 2-bromo-5,6-dichlorobenzimidazole. In contrast, the 2-iodo derivative presented a more difficult problem since the appropriate heterocycle was unavailable. This prompted us to prepare the 2-amino derivative followed by nonaqueous diazotization and removal of the blocking groups. Biological evaluation revealed marked differences in the activities of these compounds and the closely related known compound 5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole (DRB). DRB was weakly active against both human cytomegalovirus (HCMV) and herpes simplex virus type 1 (HSV-1), (IC50's = 42 and 30 microM, respectively) but was cytotoxic to uninfected human foreskin fibroblasts and KB cells in the same dose range. Similar results were obtained with the heterocycle 2,5,6-trichlorobenzimidazole. In marked contrast, the ribonucleoside of 2,5,6-trichlorobenzimidazole (TCRB) was active against HCMV (IC50 = 2.9 microM, plaque assay; IC90 = 1.4 microM, yield assay) but only weakly active against HSV-1 (IC50 = 102 microM, plaque assay). Little to no cytotoxicity was observed in HFF and KB cells at concentrations up to 100 microM. By changing the substituent at the 2-position from chlorine to bromine (BDCRB), a 4-fold increase in activity against HCMV was observed without any significant increase in cytotoxicity. In contrast, the 2-I and 2-NH2 derivatives were only weakly active against HCMV and HSV-1 with activity not well-separated from cytotoxicity. These data establish that for maximum activity against HCMV with separation from cytotoxicity, ribose is preferred at the 1-position and that Cl or Br is apparently preferred at the 2-position. The activity and selectivity of both TCRB and BDCRB were better than that observed with either ganciclovir or foscarnet.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562945     DOI: 10.1021/jm00020a025

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation.

Authors:  D G Wolf; C T Courcelle; M N Prichard; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

2.  Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Authors:  Paula M Krosky; Katherine Z Borysko; M Reza Nassiri; Rodrigo V Devivar; Roger G Ptak; Michelle G Davis; Karen K Biron; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 3.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

4.  The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Authors:  Thomas Goldner; Guy Hewlett; Nicole Ettischer; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 5.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

6.  Cytomegalovirus UL103 controls virion and dense body egress.

Authors:  Jenny Ahlqvist; Edward Mocarski
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

7.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.

Authors:  David L Evers; Gloria Komazin; Roger G Ptak; Dongjin Shin; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.

Authors:  Gloria Komazin; Roger G Ptak; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides.

Authors:  Jae-Seon Hwang; Rita Schilf; John C Drach; Leroy B Townsend; Elke Bogner
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.